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Hepatocellular carcinoma (HCC) is a widespread
fatal disease and the third most common cause of
cancer deaths. Here, we show the potent anti-HCC
effect of the circulating protein AIM. As in adipo-
cytes, AIM is incorporated into normal hepatocytes,
where it interferes with lipid storage. In contrast,
AIM accumulates on the HCC cell surface and
activates the complement cascade via inactivating
multiple regulators of complement activation. This
response provokes necrotic cell death specifically
in AIM-bound HCC cells. Accordingly, AIM/ mice
were highly susceptible to steatosis-associated
HCC development, whereas no AIM+/+ mouse devel-
oped the disease despite comparable liver inflamma-
tion and fibrosis in response to a long-term high-fat
diet. Administration of AIM prevented tumor devel-
opment in AIM/mice, and HCC induction by dieth-
ylnitrosamine was more prominent in AIM/ than
wild-type mice. These findings could be the basis
for novel AIM-based therapeutic strategies for HCC.
INTRODUCTION
Chronic liver injury, one of the most common and fatal diseases,
has multiple causes including hepatitis virus infection, alcohol
and toxins, autoimmunity, and genetic disorders such as hemo-
chromatosis (Bosch et al., 2005; El-Serag and Rudolph, 2007;
Jemal et al., 2011). In addition, due to rapid and drastic changes
in lifestyle and eating habits in modern society, obesity-associ-
ated nonalcoholic fatty liver disease (NAFLD), which comprises
a wide variety of disease criteria ranging from benign simplesteatosis to progressive inflammation and fibrosis called nonal-
coholic steatohepatitis (NASH), has been observed in a rapidly
growing number of patients (Powell et al., 1990; Day and Sak-
sena, 2002; Angulo, 2002; Harrison et al., 2003; El-Serag and Ru-
dolph, 2007; Ascha et al., 2010; Nordenstedt et al., 2010; Blonski
et al., 2010). Such chronic liver diseases are prominent risk fac-
tors for the development of hepatocellular carcinoma (HCC)
because of the continuous liver inflammation and fibrosis that
follows (Hytiroglou et al., 2007; He and Karin, 2011; Park et al.,
2010). In particular, crucial roles of interleukin-6 (IL-6) in liver
inflammation and further progression to HCC have been high-
lighted (Hytiroglou et al., 2007; He and Karin, 2011; Park et al.,
2010). Interestingly, it has recently become apparent that
although HCC develops largely under cirrhotic background, it
often occurs without severe fibrosis/cirrhosis in NAFLD/NASH
patients (Chagas et al., 2009; Kawada et al., 2009; Paradis
et al., 2009; Starley et al., 2010; Takuma and Nouso, 2010; Ertle
et al., 2011; Torres and Harrison 2012). In addition to such
increasing risks and complicated pathogenesis, HCC is well
known as an inherently chemotherapy-resistant tumor express-
ing the multidrug-resistant gene MDR-1 (Kuo et al., 1992; Huang
and Liu, 1999; Kato et al., 2001). Hence, the development of suf-
ficient therapeutic strategies for HCC is strongly desired.
We recently found that the apoptosis inhibitor of macrophage
(AIM; also called CD5L), a circulating protein initially identified as
a supporter of macrophage survival (Miyazaki et al., 1999; Arai
et al., 2005), plays a preventive role in obesity progression (Kur-
okawa et al., 2010). Interestingly, AIM associates with the immu-
noglobulin M (IgM) pentamer in blood, which protects AIM from
renal excretion and thus maintains circulating AIM at a relatively
high concentration (about 2.5–10 mg/ml) (Arai et al., 2013; Tissot
et al., 2002). We found that circulating AIM is incorporated into
adipocytes via CD36-mediated endocytosis, where it inactivates
cytoplasmic fatty acid synthase (FASN) through direct binding.
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proteins such as fat-specific protein 27 (FSP27) and Perilipin,
thereby decreasing triacylglycerol deposition within adipocytes
(Kurokawa et al., 2010; Iwamura et al., 2012). Accordingly, in
AIM/ mice fed a high-fat diet (HFD), adipocyte hypertrophy
was more advanced and the mass of visceral adipose tissues
was greater than in AIM+/+ mice fed an HFD. This HFD-induced
hyperobese phenotype was abolished by administering recom-
binant AIM (rAIM) to the AIM/ mice (Kurokawa et al., 2010,
2011).
In view of these findings showing that AIM blocks lipid storage
in adipocytes, we investigated the role of AIM in NAFLD andHCC
development using AIM/mice fed an HFD. Unexpectedly, this
study revealed an AIM-dependent cascade of cancer cell elimi-
nation, which strongly prevents HCC development. Thus, in
this report, we demonstrate the preventive role of AIM in steato-
sis-associated HCC and present our finding of the mechanism
throughwhich AIM specifically eliminates cancer cells in the liver.
RESULTS
HCC Development in Obese AIM/ Mice
When fed an HFD for 1 year (52 weeks), all AIM/ mice devel-
oped multiple liver tumors (Figure 1A). Histological analysis
revealed that the tumors exhibited typical HCC, which stained
positive for gp73 (Marrero et al., 2005; Bao et al., 2013) and
Hep Par 1 (Fan et al., 2003) (Figure 1A). In contrast, no AIM+/+
mice demonstrated such multiple HCC tumors macroscopically
or histologically after the same HFD challenge (Figure 1A). This
observation is consistent with the findings of previous reports
by other groups who showed that HCC is hardly induced in
wild-type mice by HFD challenge alone (Yoshimoto et al.,
2013; Hill-Baskin et al., 2009). When analyzed at different time
points during the HFD challenge, HCC was detected in 10% of
AIM/ mice (2 of 21) after a 12-week HFD, and the incidence
rapidly increased thereafter (Figure 1B). The mRNA level for
alpha-fetoprotein (AFP) profoundly increased in the tumor areas
developed in AIM/ mice fed an HFD for 1 year (Figure 1C).
To corroborate that the difference in HCC incidence between
AIM/ and AIM+/+ mice was solely dependent on circulating
AIM, AIM/ mice were injected intraperitoneally with rAIM
(200 mg/mouse/week, n = 5) or PBS (n = 5) when fed an HFD.
Mice were fed an HFD for 45 weeks and the injection was started
after week 12. After the HFD challenge for 45 weeks, in contrast
to the 80%occurrence of HCC tumors inmice injectedwith PBS,
no development of HCC tumor was observed in any of the mice
injected with rAIM (Figure 1D). Careful histological analysis re-
vealed some gp73-positive cells in rAIM-challenged mice, but
at much lower numbers than in the mice injected with PBS (Fig-
ure 1E). Interestingly, the overall circulating AIM levels after the
injection varied among the mice, and fewer gp73-positive cells
were observed in mice with higher circulating AIM levels (Figures
1E and 1F).
States of Steatosis, Inflammation, and Fibrosis in the
Liver of AIM/ Mice
In accordance with the hyperobese phenotype (Kurokawa et al.,
2010), progression of liver steatosis in response to an HFD was
also accelerated both macroscopically and histologically in62 Cell Reports 9, 61–74, October 9, 2014 ª2014 The AuthorsAIM/ mice compared with AIM+/+ mice (Figures 2A and
S1A). Consistently, the increase in liver weight and triacylglycerol
content along with obesity was more obvious in the AIM/mice
(Figure 2B). We confirmed that AIM suppresses lipid deposition
in the liver through the samemechanism as that in adipose tissue
and consequently inhibits the progression of steatosis. Experi-
mental data for this conclusion are shown in Figures S1B–S1G
and the Supplemental Results.
It is well known that the chronic liver inflammation and
following fibrosis are prominent risk factors for the development
of HCC. Under obese conditions, such a subclinical inflamma-
tory state is brought about by excess cell stress, particularly
oxidative stress, caused by lipid overload in hepatocytes (Seki
et al., 2002; Browning and Horton, 2004). Interestingly, although
the cell stress state in the liver appeared to be more enhanced
in AIM/ mice in line with advanced steatosis, as judged by a
significant difference in mRNA levels in some stress-responsive
genes in AIM/ and AIM+/+ liver (Figure 2C), both types of mice
showed essentially comparable levels of liver inflammation dur-
ing the progression of liver steatosis. The mRNA levels of inflam-
matory cytokines in the liver were similar in obese AIM/ and
AIM+/+ mice. IL-1b expression levels were even lower in the liver
of AIM/ mice than in AIM+/+ mice (Figure 2D). In addition, no
increase in mRNA levels for such inflammatory genes was
obvious in liver Kupffer macrophages isolated from obese
AIM–/– mice compared with those from AIM+/+ mice (Figure 2E).
In line with these results, liquid-chromatography mass-spec-
trometry-based metabolomics analysis of the liver from mice
fed an HFD for 12 weeks revealed a similar lipid profile in both
the AIM/ and AIM+/+ mice, showing no obvious increase in
proinflammatory lipid metabolites in AIM/ liver (Figure S2).
Consistent with the finding of a similar inflammatory state, liver
fibrosis progressed comparably in AIM/ and AIM+/+ liver (Fig-
ures S3A and S3B). This was also true in AIM/ mice with tu-
mors fed an HFD for 45 or 55 weeks when the nontumor area
of AIM/ liver was compared with AIM+/+ liver (Figure S3B).
Furthermore, microarray analysis of AIM/ and AIM+/+ liver
showed no significant difference in the magnitude of expression
of fibrosis-related genes during steatosis progression (Table S1).
In particular, mRNA levels of Collagen-type I-alpha 1 and Actin-
alpha2, representative fibrogenic genes, were comparable in
AIM/ and AIM+/+ liver when assessed by quantitative polymer-
ase chain reaction (Figure S3C). Consistent with these results,
the activation state of hepatic stellate cells, the most responsible
cell type for liver fibrosis, was similar in AIM/ and AIM+/+ mice
as judged by the comparable expression of alpha smooth mus-
cle actin (aSMA) in immunohistochemistry (Figure S3D).
Based on these findings, it is likely that AIM/ and AIM+/+
mice were equally susceptible to HCC. Indeed, microarray anal-
ysis revealed no significant differences in the expression of
genes for cancerization-related canonical pathways in AIM/
and AIM+/+ liver in response to an HFD (Table S2). In addition,
the phosphorylation states of AKT and ERK, key mediators of
tumorigenesis activation, were comparable between AIM/
and AIM+/+ liver (Figure S3E). Therefore, we hypothesized that
the mechanism of HCC prevention by AIMmight involve elimina-
tion of cancerized cells rather than influencing the susceptibility
to cancerization of hepatocytes.
Figure 1. HCC Development in AIM/ Mice
(A) Representative photomicrographs of the liver from AIM+/+ and AIM/mice fed an HFD for 1 year. Whole liver and histological images; hematoxylin and eosin
(H&E) staining and immunohistostaining for gp73 (magenta) and Hep Par 1 (red) are shown.
(B) Incidence of HCC in AIM+/+ and AIM/ mice fed an HFD for the indicated number of weeks. At each time point, more than ten mice of each genotype were
analyzed.
(C) ThemRNA levels assessed by quantitative PCR forAFP in the liver inAIM+/+ andAIM/ fed an HFD for the indicated number of weeks. At 50weeks, nontumor
and tumor (only in AIM/ mice) areas were separately assessed. n = 3–6 per group. Error bar, SEM.
(D) AIM/mice were fed an HFD for 45 weeks and intraperitoneally injected with rAIM (200 mg/mouse/week) or PBS after 12 weeks (n = 5 per group). Mice were
then sacrificed, and the incidence of HCC tumor was determined.
(E) Histological photomicrographs of the liver from the mice in a. Liver specimens were immunohistostained for gp73. At least five sections from three lobes per
mouse were analyzed.
(F) Blood AIM levels at the time of liver analysis addressed by immunoblotting are also shown. In rAIM-injected mice, blood AIM levels varied, and the number of
gp73-positive cells in the liver was less in mice with relatively higher AIM levels.Accumulation of AIM on the Surface of HCC Cells
To determine whether AIM directly affects HCC cell viability, we
treated Hepa1.6 cells, an HCC cell line derived from the C57BL/6
(B6) mouse, with rAIM and evaluated cell death. No obvious in-
crease in dead propidium iodide-positive cells was observed af-
ter the rAIM challenge, suggesting no direct cell killing effect ofAIM (data not shown). Interestingly, however, during this exper-
iment, we found that unlike the primary normal hepatocytes,
which endocytosed AIM (Supplemental Results; Figures S1B
and S1C), Hepa1.6 cells did not incorporate AIM but accumu-
lated AIM on their cell surface. When Hepa1.6 cells were incu-
bated with plasma from wild-type mice, immunocytostainingCell Reports 9, 61–74, October 9, 2014 ª2014 The Authors 63
Figure 2. Advanced Steatosis but Comparative Conditions of Liver Inflammation in AIM/ Mice
(A) Representative photomicrographs of the liver from AIM+/+ and AIM/ mice fed an HFD.
(B) Liver weight and liver triacylglycerol (TG) content in AIM+/+ and AIM/ mice fed an HFD for the indicated number of weeks. n = 6 per group. Error bar
represents SEM.
(C) The mRNA levels of various genes responsive to different types of stresses (i.e., endoplasmic reticulum [ER], mitochondrial, or oxidative stress) addressed by
quantitative PCR using RNA from whole liver of AIM+/+ and AIM/ mice fed an HFD for the indicated numbers of weeks. Hydrogen peroxide measured using
(legend continued on next page)
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revealed a substantial deposition of AIM on the cell surface
(Figure 3A), whichwas confirmed by flow cytometry (Figure 3B).
Consistent with the complex formation of AIM and IgM in
blood (Arai et al., 2013), IgM was also detected on the cell
surface (Figures 3A and 3B). AIM alone bound to the cell sur-
face but at a lower level when tested with rAIM (Figure 3B).
Because the IgM pentamer is associated with multiple (up to
five) AIM molecules, formation of an AIM/IgM complex may
have the advantage of enabling accumulation of more AIM on
the cell surface. In fact, some human HCC cell lines showed
a similar accumulation of human AIM on their cell surface
(Figure 3C).
We next addressed whether this finding holds true in the liver
of AIM/ mice fed an HFD. We injected rAIM via a mesenteric
vein into the liver of AIM/ mice fed an HFD for 35 weeks and
evaluated the accumulation of rAIM on the surface of hepato-
cytes under a confocal microscope. Lean AIM/mice were em-
ployed as controls. As shown in Figure 3D, no AIM signal was
observed on the surface of the hepatocytes in lean AIM/ liver.
In contrast, AIM signals colocalized with IgM were apparent on
the surface of hepatocytes in many, but not all, areas of the liver
inAIM/mice fed an HFD (Figure 3D). These AIM-stained hepa-
tocytes had progressed to cancer, as indicated by their positive
staining for the HCCmarker gp73 (Figure 3D). InAIM/mice fed
an HFD for more than 50 weeks, in which a number of HCC nod-
ules were observed, injected rAIM was stained on the surface of
many cells within the tumors at various levels, again colocalizing
with IgM (Figure 3D). The staining level for gp73 was higher than
that in mice fed an HFD for 35 weeks, possibly suggesting that
AIMmay start to accumulate on the cell surface at preneoplastic
stage. We confirmed the presence of AIM on the cell surface by
analyzing the colocalization of the signals for AIM and wheat
germ agglutinin, which is found predominantly on the cell mem-
brane (Figure S4A). Taken together, these findings indicate that
AIM accumulates on the cell surface of cancerized, but not
normal, hepatocytes.
It is widely accepted that derailed endocytosis is a hallmark of
many types of cancer cells. This characteristic results in defec-
tive vesicular trafficking of growth factor receptors, as well as un-
balanced recycling of integrin- and cadherin-based adhesion
complexes, leading to unlimited cell growth through self-suffi-
ciency in growth signals and tissue invasion (Polo et al., 2004;
Mosesson et al., 2008). Since AIM is incorporated into normal
hepatocytes by endocytosis, defective endocytosis might ac-
count for the retention of AIM on the surface of HCC cells.
Accordingly, the mRNA levels of various elements that mediate
the endocytotic pathway through different mechanisms (e.g.,
dynamin2, esp15, cbl, spry2, and pard3) (Fang and Xu, 2001;
Fong et al., 2006; Gilleron et al., 2011; Sargin et al., 2007; So
et al., 2003) showed varying reduced levels in tumor lesions
compared with nontumor lesions in AIM/ liver or with AIM+/+
liver (Figure 3E).hydrogen peroxide colorimetric assay kit (BioVision Technologies) and 8-OHdGm
Error bar, SEM.
(D and E) Inflammatory states in the liver. The mRNA levels for proinflammatory cy
(n = 5–6); (E) Kupffer macrophages isolated from HFD-fed (12 weeks) mice (n = 3Necrotic Cell Death Induction in HCC Cells In Vivo by
Cell-Surface-Bound AIM
While AIM had no direct killing effect on Hepa1.6 cells in vitro, we
considered whether AIM accumulation on the cell surface might
affect HCC cell viability in vivo. We therefore generated Hepa1.6
cells expressing membrane-bound AIM (MB-AIM/Hepa1.6;
Figure 4A) and inoculated them together with intact Hepa1.6
cells in AIM/ liver. The membrane-bound AIM was designed
to contain a mouse CD5 transmembrane domain and a partial
cytoplasmic domain, which have no signaling potential (Bam-
berger et al., 2011), at the C terminus (Figure 4A). As shown in
Figure 4B, a number of tumors developed in 1 week, and most
were negative for AIM; namely, they were derived from intact
Hepa1.6 cells. This result suggests that the presence of AIM
on the cell surface inhibits the growth of Hepa1.6 cells in the liver.
To investigate the effect of surface AIM in detail, we created
another type of Hepa1.6 cell line in which expression of mem-
brane-bound AIM can be induced by doxycycline (iMB-AIM/
Hepa1.6). When inoculated in AIM/ liver, the iMB-AIM/
Hepa1.6 cells developed multiple tumors, as did the intact
Hepa1.6 cells, and challenge with doxycycline via intravenous in-
jection clearly induced AIM expression on the surface of tumor
cells (Figure 4C). Remarkably, membrane-bound AIM expression
resulted in specific tumor cell death (Figure 4D). In particular, 6 hr
after the doxycycline injection, staining for Ki67, amarker of cell di-
vision, revealed both surviving tumor cells (highly positive Ki67
expression) and dying tumor cells (low to negative Ki67 expres-
sion) (Figure 4E). Within 6–12 hr, Ki67 was reduced or lost in
most of the remaining tumor cells, and the average tumor size
was also markedly reduced (Figures 4D and 4E). Electron micro-
scopy of the tumor area after the doxycycline injection revealed
cells harboring shrunken and condensed nuclei and destroyed
cytoplasmic organelles, which are features of necrotic cells (Fig-
ure 4F). In support, the dying tumor cells were negative for TUNEL
staining, showing that the cell deathwasnot due toapoptosis (Fig-
ure S5). Some dead cells were already removed by accumulating
F4/80+Kupffermacrophages (Figure4G).Within 24hr,manyof the
tumors had been eliminated from the recipient liver (Figure 4D).
Similarly, when an injection of rAIM via mesenteric vein was
given to challenge AIM/ mice in which intact Hepa1.6 cells
had developed tumors, AIM deposition was observed on the tu-
mor cell surface, and some tumors exhibited cell death (Fig-
ure 4H). In accordance with this finding, when the Hepa1.6 cells
were inoculated into the liver of AIM+/+ or AIM/mice, the num-
ber of HCC tumors that developed in 1 week was significantly
larger in AIM/ liver (Figure 4I). In addition, rAIM (200 mg/injec-
tion, three times per week) or PBS was intravenously injected
for 3 weeks into AIM/ mice with HCC tumors, which had
been fed an HFD for 46 weeks, and the state of HCC was as-
sessed (two mice for each group). Both PBS-injected mice
possessed multiple HCC tumors, whereas one of the two
rAIM-injected mice had no HCC nodule (Figures S6A and S6B).easured by 8-OHdG check ELISA (Wako) are also presented. n = 5–6 per group.
tokine genes in the liver of AIM+/+ and AIM/mice fed an HFD. (D) Whole liver
). Error bar, SEM.
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Intriguingly, remaining HCC tumors in the other rAIM-injected
mouse were largely negative for AIM deposition (Figure S6C),
suggesting that tumors that could not successfully accumulate
AIM on the cell surface were not sufficiently removed.
Activation of Complement Cascade by AIM
Accumulation on the Tumor Cell Surface
Such efficient necrosis induction in an indirect manner led us to
address whether the complement-dependent cytotoxicity (CDC)
might be involved in the mechanism of AIM-dependent HCC cell
death. Interestingly, following the induction of membrane-bound
AIM, accumulation of complement component C3 on the tumor
cell surface was detected, suggesting activation of the com-
plement cascade against the tumor cells (Figure 5A). In parallel,
the membrane attack complex (MAC), the overall effector
comprising C5b-C9 as the result of complement cascade activa-
tion (Mu¨ller-Eberhard, 1986), was specifically stained in tumor
cells (Figure 5B). To corroborate the involvement of comple-
ments in AIM-associated HCC cell damage, we transplanted
the MB-AIM/Hepa1.6 cells, which constitutively expressed
membrane-bound AIM (Figure 4A), with the intact Hepa1.6 cells
(106 cells for each) in the liver of AIM/ and C3/ mice. Flow
cytometry of collagenase-digested liver tissue revealed that a
large proportion of the cells that had grown in the AIM/ liver
were negative for membrane-bound AIM, consistent with the re-
sults presented in Figure 4B. However, as expected, both MB-
AIM/Hepa1.6 cells (positive for cell-surface AIM) and intact
Hepa1.6 cells (negative for cell-surface AIM) were equally de-
tected in C3/ liver (Figure 5C). Immunohistochemical analysis
of both types of the liver tissue supported this finding (Figure 5C,
histologic images).
When fed an HFD for more than 75 weeks (about 1.5 years),
HCC development was occasionally observed in a few AIM+/+
mice, though the tumor was often solitary, in contrast to the mul-
tiple nodules seen in AIM/ mice. Deposition of endogenous
AIM as well as C3 was also observed in the tumors that devel-
oped in the AIM+/+ mice (Figure 5D). Interestingly, the tumor cells
with strong accumulation of AIM and C3 appeared to be
damaged as they exhibited distorted cell and nuclear mem-
branes (indicated by white arrows), whereas those without
obvious AIM deposition were intact (indicated by red arrows).
This result is consistent with the observation that remaining
HCC tumors in AIM/ mice after frequent rAIM injections were
negative for AIM deposition (Figure S6).
To understand the mechanism of how AIM accumulation on
the tumor cell surface activates the complement cascade, weFigure 3. AIM Accumulation on the HCC Cell Surface
(A) Hepa1.6 cells were incubated with serum from wild-type or AIM/mice at a 5
(green), and DAPI, and analyzed under a confocal microscope.
(B) Hepa1.6 cells were incubated as described above, or with rAIM (20 mg/ml), a
(C) Flow cytometry of various human HCC cells (HepG2, Alexander, Huh7) for su
Mean fluorescence intensity (MFI) is shown. Sera from healthy volunteers (numb
(D)AIM/mice fed an HFD for 0, 35, or 52weekswere injected with rAIM (500 mg/
stained for AIM (green), IgM (red), and gp73 (magenta). As a control, liver specime
(green) signal was detected in gp73-positive tumor cells.
(E) Quantitative PCR analysis of mRNA levels for endocytosis-related genes in m
AIM/ liver, as well as AIM+/+ liver without tumor, were analyzed. n = 5 per group.
AIM/ liver. Error bar, SEM.focused on the regulators of complement activation (RCAs). Un-
like bacterial cells, mammalian cells are usually protected from
complement-dependent autologous attack by a series of RCAs
present on the cell membrane (Kojima et al., 1993; Medof
et al., 1984; Miwa and Song, 2001). A number of studies have
demonstrated that inhibition of RCAs enhances the CDC against
variable tumor cells (Ho¨rl et al., 2013; Imai et al., 2004; Ohta et al.,
2004). Thus, our observation indicates that the RCAs were less
effective when AIMwas present on the cell surface. Accordingly,
a coimmunoprecipitation assay revealed that AIM bound directly
to multiple RCAs that suppressed C3 activation (i.e., CD55,
complement regulator complement receptor 1-related gene/
protein-y, and complement factor H) or MAC formation (i.e.,
CD59) (Figure 5E). Based on these results, it is likely that on
the tumor cell surface, AIM might have interfered with the com-
plement regulatory activity of the RCAs through direct associa-
tion, thereby triggering CDC activation. To support this idea,
unlike what would be expected with lipopolysaccharide (LPS),
AIM itself did not directly activate C3 or the subsequent comple-
ment cascade when tested in vitro using the cell-free system to
assess the activation state of the complement cascade (Fredrik-
son et al., 1993; Seelen et al., 2005) (Figure S7A).
Overall, the presence of AIM on the cell surface activated the
CDC cascade through inactivating RCAs, thereby inducing
necrotic cell death in the HCC cells, and the dead cells were
then removed by Kupffer macrophages. It is noteworthy that
that expression of membrane-bound AIM in cultured Hepa1.6
cells did not induce cell death (Figure S7B), similar to the obser-
vation that in vitro treatment of Hepa1.6 cells with rAIM did not
influence cell viability. Thus, cell-surface AIM itself is not cyto-
toxic but induces cell death in an indirect manner through CDC
activation.
Effect of AIM on Obesity-Independent HCC
Lastly, we addressedwhether AIM can effectively suppress HCC
development in a model not associated with obesity. Therefore,
we employed an HCC model induced by diethylnitrosamine
(DEN) (Verna et al., 1996), a highly carcinogenic compound.
AIM/ and the littermate AIM+/+ or AIM+/ neonates were chal-
lenged with DEN, and tumor development was assessed at 4, 6,
and 9 months of age. Although DEN-induced HCC tumors are
expected to be apparent after 8 or 9 months (He et al., 2013),
we also performed analysis at earlier periods as we expected
advanced tumor development in AIM/ mice. As expected, at
4 and 6 months, the number of HCC tumors was significantly
higher in the AIM/mice than in the littermate mice (Figure 6A).0% concentration (v/v) for 4 hr. Cells were then stained for AIM (magenta), IgM
nd analyzed by flow cytometry.
rface AIM accumulation after challenge with human serum (50% v/v) for 4 hr.
ered) are used. White bar, no serum (cont.).
mouse) via amesenteric vein, and 4 hr later, liver specimens were prepared and
ns frommice without rAIM injection were stained for AIM and gp73, and no AIM
ice fed an HFD for 52 weeks. RNA isolated from tumor and nontumor areas of
White bar, AIM+/+ liver; black bar, no-tumor area (N); gray bar, tumor area (T) of
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Figure 4. Cell-Surface AIM Induces Tumor Cell Death In Vivo
(A) Structure of membrane-bound (MB) AIM and flow cytometry analysis of cell-surface expression. The transmembrane region (amino acids residues 372–401)
and a short cytoplasmic tail (amino acids residues 402–407; YKKLVK) frommouse CD5, and an additional hemagglutinin (HA) tag were fused to the C terminus of
mouse AIM. A DNA fragment of the vector plasmid for MB-AIM expression was stably transfected to Hepa1.6 cells.
(B) AIM/ mice were injected with a mixture of MB-AIM/Hepa1.6 and intact Hepa1.6 cells (5 3 105 cells each), and 1 week after the injection, tumors were
analyzed by staining liver specimens for AIM and gp73. The overall percentage of AIM-positive and AIM-negative cells in all tumor cells of five sections from three
lobes in three mice is shown.
(C) To obtain iMB-AIM/Hepa1.6, two DNA fragments were created using Tet-On Advanced Inducible Gene Expression System (Life Technologies) and stably
transfected to Hepa1.6 cells. Intraperitoneal injection of doxycycline (50 mg) induced surface AIM (red) in iMB-AIM/Hepa1.6-derived tumors that developed in the
liver of AIM/ mice.
(D) Doxycycline (50 mg) was intraperitoneally administrated into AIM/ mice with iMB-AIM/Hepa1.6-derived tumors in the liver, and the state of tumors was
histologically analyzed at different time points by staining with H&E. Representative photomicrographs are shown. At least three mice at each time point were
analyzed, and similar results were obtained.
(E) Immunohistostaining for Ki67 (red) before (0h) and 6 hr after the doxycycline injection.
(F) Electronmicroscopy of the tumor area before (0h) and after (7h) the doxycycline injection. Liver tissue containing tumorswas fixed by in 4%paraformaldehyde,
0.05%glutaraldehyde in PBS (pH 7.2) with a postfixation in osmium tetroxide and then stained with lead citrate and uranyl acetate. Samples were examined using
(legend continued on next page)
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Figure 5. Activation of Complement
Cascade by AIM on the Tumor Cell Surface
(A and B) Liver specimens from mice before and
2 hr after the doxycycline injection were stained for
C3 (red; arrowed) (A) or MAC (orange) (B).
(C) MB-AIM/Hepa1.6 and Hepa1.6 cells (106 cells
each) were transplanted into the liver of AIM/ or
C3/mice, and 1week after the injection, the liver
was digested by collagenase as done in primary
hepatocyte isolation (see Experimental Pro-
cedures). Cells were stained for cell-surface AIM
and analyzed by flow cytometer. As both types of
cells also stably express GFP, the histograms
show AIM expression in GFP-positive cells. Three
experiments were performed and similar results
were obtained. Representative flow-cytometric
and immunohistochemical results are presented.
In immunohistochemistry, AIM (green) and DAP
(blue) were stained.
(D) Liver specimens from wild-type mice with HCC
tumor were stained for AIM (green) and C3 (red).
The tumor cells with strong accumulation with AIM
and C3 appeared to be damaged (white arrows),
whereas those without AIM deposition were intact
(red arrows).
(E) The association between AIM and the indicated
RCA molecule in HEK293T cells tested by coim-
munoprecipitation assay using an anti-Flag, anti-
HA, or anti-AIM. CD55, CD59, and Crry were HA
tagged, whereas CFH was Flag tagged. Flag-
tagged AIM was used, except in the case tested
with Flag-tagged CFH.In particular, tumor development was obvious only in AIM/
mice at 4 months both macroscopically and histologically (Fig-
ure 6B). At 9 months, although the tumor number had reached
similar levels in both AIM/ and the littermate mice, the average
tumor size was significantly larger in the AIM/mice than in the
littermate mice (Figures 6A and 6C, left panels). Note that in the
absence or presence of AIM, the mRNA level for AFP in tumor
areas was comparable, indicating similar HCC characteristics
(Figure 6C, right panel). In the AIM/ mice, AIM accumulation
on the tumor cell surface was observed following rAIM injectionHitachi H7000 electron microscope. Dying tumor cells are indicated by arrows. Macrophage (M) and polym
region are also indicated. Magnification: 32,000.
(G) Immunostaining for F4/80 (red) before (0h) and after (2h) the doxycycline injection.
(H) rAIM (200 mg) was injected into AIM/mice with HCC tumors derived fromHepa1.6 five times (one injectio
and liver specimens were stained for AIM (red) as well as with H&E.
(I) Hepa1.6 cells (13 106) were inoculated into the liver ofAIM+/+ andAIM/mice via amesenteric vein. Onew
developed liver tumors were evaluated by gp73 and H&E staining. Three sections of three lobes were analyz
analyzed. The average tumor numbers per section are shown. Error bar, SEM.
Cell Reports 9, 61–7(Figures 6D and S4B). The suppressive
effect of tumor development in the pres-
ence of AIM appeared to be milder in
DEN-induced HCC compared with that
observed in HFD-induced HCC. A plau-
sible explanation for this difference may
be the less sufficient increase in blood
AIM in wild-type mice in response to
DEN compared with HFD assessed byimmunoblotting (Figure 6E). Alternatively, DEN-induced HCC
cells might be more resistant to the complement attack induced
by AIM (e.g., due to their higher proliferative activity). It will be
interesting to assess possible difference in characteristics be-
tween DEN- and HFD-induced HCC in AIM/ mice.
DISCUSSION
This study provides an approach for preventing HCC progres-
sion (Figure 7). We postulated that overall HCC tumororphonuclear leukocytes (PMN) infiltrated to tumor
n/day). After the last injection, mice were sacrificed
eek after the inoculation, the number and the size of
ed per mouse. Three mice of each genotype were
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Figure 6. Effect of AIM on DEN-Induced HCC
(A) The number of HCC tumors in 4-, 6-, and 9-month-old AIM/ and the littermate AIM+/+ or AIM+/ mice that had been challenged with DEN. The average
number of tumors per group (n = 5) is shown. At 9 months old, the number was similar in both types of mice, but the average tumor size was significantly larger in
AIM/ mice. Tumor size: S, <2 mm4; M, 2–5 mm4; L, >5 mm4. Error bar, SEM.
(B) Representative macroscopic and histological (H&E) photomicrographs of 4- and 6-month-old AIM/ and the littermate AIM+/+ or AIM+/mice that had been
challenged with DEN. In macroscopic photomicrographs, tumors are indicated by arrows. H&E staining results of the tumor areas are presented.
(C) Nine-month-old AIM/ and the littermate AIM+/+ or AIM+/mice challenged with DEN. Left: representative macroscopic and H&E photomicrographs. Right:
mRNA levels for AFP in tumor and nontumor areas in the liver. n = 3–5 for each group.
(D) rAIM (500 mg) was injected into 9-month-old DEN-challengedAIM/mice. At 4 hr after the injection, micewere sacrificed and liver specimenswere stained for
AIM and gp73. Representative photomicrographs are shown.
(E) Immunoblotting for blood AIM in wild-type mice challenged with HFD or DEN. Three mice for each group were analyzed.
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Figure 7. Schematic Summary for the Role
of AIM in HCC Prevention
With progression of liver steatosis, hepatocytes
undergo cancerization, which is brought about by
liver inflammation and fibrosis that follows. This
process is not influenced by AIM, as inflammation
and fibrosis states comparatively progress in
response to high-fat diet (HFD), in the presence or
absence of AIM. In the presence of AIM, however,
AIM accumulates on the surface of cancerized he-
patocytes and activates the complement cascade.
This response induces necrotic death in cancerized
cells, resulting in efficient prevention of hepato-
cellular carcinoma (HCC) tumor development. In
contrast, in the absence of AIM, cancerized hepa-
tocytes are not eliminated and progressed to mul-
tiple HCC tumors.progression is inhibited by CDC-dependent HCC cell elimination
in the presence of AIM. Our experiments showed C3 deposition
and MAC formation on the tumor cells immediately after induc-
tion of AIM on their cell surface, which was likely associated
with the inhibition of multiple complement-inactivating RCAs
by AIM though direct binding. Surface-bound AIMmight interfere
with the access of RCAs to complements, although its precise
mechanism remains unclear. The tumor cell killing process initi-
ated byC3 accumulation on the cell surface is reminiscent of that
of germicide through the antibody-independent CDC pathway
(known as the alternative pathway). In addition, it is possible
that antibody-dependent CDC activation (known as the classical
pathway), which is triggered by the binding of complement C1q
to IgM, leading to overall C3 activation and deposition on the cell
surface, might also be stimulated through AIM, since AIM
engaged IgM on the tumor cell surface (Figures 3A and 3B).
Furthermore, based on the finding by Sarrias and colleagues
that LPS binds to AIM (Sarrias et al., 2005), it is possible that
intrahepatic LPS influxed from the intestine is associated with
cell-surface AIM, thereby activating the CDC activity, as in bac-
teria-killing systems. Thus, on the tumor cell surface, different
CDC pathways might be simultaneously mobilized by AIM to
enhance its killing activity. Further experiments are needed
to verify this possibility. Intriguingly, intrahepatic LPS is certain
to promote HCC development by inducing chronic inflammation
and subsequent fibrosis through Toll-like receptor 4 stimulation
in non-bone marrow-derived resident liver cells, as clearly
demonstrated by Dapito et al. (2012). Hence, although LPS is
detrimental as it enhances cancerization of hepatocytes via
creating an oncogenic environment in the liver, it might also be
beneficial because it promotes elimination of cancerized hepato-
cytes. Additional experiments will also address this issue.
Frequent intravenous injections of rAIM resulted in partial tu-
mor regression in AIM/ mice with multiple HFD-induced
HCC nodules (Figure S6), contrastive to the rapid and sufficient
tumor clearance observed in iMB-AIM/Hepa1.6 cells upon
expression of membrane-bound AIM (Figure 4D). This difference
might be due to the level of cell-surface AIM in each model.
Furthermore, the constitutive presence of AIM on the tumor
cell surface is expected in iMB-AIM/Hepa1.6 cells, but probably
not in rAIM-injected AIM/ mice. During HCC development inwild-type mice fed an HFD, blood AIM is constitutively present
at a high concentration, and moreover, the subsequent AIM
accumulation and necrosis induction in cancerized cells should
be induced before tumor enlargement. Such conditions may
be advantageous for efficiently preventing tumor development.
It is noteworthy that remaining HCC tumors in rAIM-injected
AIM/ mice were negative for AIM deposition (Figure S6).
Thus, it is likely that the intravenous injectionmay not be effective
to accumulate rAIM to HCC. It might be possible that a large pro-
portion of injected rAIM is incorporated to other cell types or
excreted into urine before reaching HCC tumors. Indeed, HCC
tumors were largely positive for AIM deposition when rAIM was
injected viamesenteric vein that directly flows to the liver via por-
tal vein (Figure 3D). Additional efforts, particularly with a focus on
identifying the appropriate dose and frequency of AIM adminis-
tration, as well as the access routes to HCC, may provide a basis
for establishing a sufficient therapeutic protocol.
It may be worth asking whether AIM can eliminate different
types of cancer cells. Since AIM is likely retained on the surface
of cancer cells originating from a cell type capable of incorpo-
rating AIM, when cells expressing CD36 and/or other scavenger
receptors that mediate AIM endocytosis (Kurokawa et al., 2010)
progress to cancer, AIM might accumulate on their cell surface
and trigger CDC activation, thereby inducing tumor cell death.
Note, however, that most complements are highly produced by
hepatocytes and that the local AIM concentration within the liver
may be higher than in other organs as Kupffermacrophages are a
major producer of AIM. Therefore, it is possible that AIM-induced
tumor killing is most effective in the liver, but further studies using
different cancer animal models in the presence or absence of
circulating AIM are needed to answer this question.
Lastly, in addition to inefficient tumor elimination, one might
argue that obese AIM/ mice are more susceptible to cancer
cell development (i.e., hepatocyte cancerization). It is known
that HCC often occurs without severe fibrosis/cirrhosis in
NAFLD/NASH patients, implicating an unknown mechanism
that promotes HCC in a fibrosis-independent fashion (Chagas
et al., 2009; Kawada et al., 2009; Paradis et al., 2009; Starley
et al., 2010; Takuma and Nouso, 2010; Ertle et al., 2011; Torres
and Harrison 2012). Certainly, steatosis was markedly advanced
in AIM/mice in response to HFD, and thus, AIM/mice mightCell Reports 9, 61–74, October 9, 2014 ª2014 The Authors 71
be susceptible to HCC through the fibrosis-independent mecha-
nismof hepatocyte cancerization. From this point of view,AIM/
mice can also be a good resource for investigating the mecha-
nism responsible for NAFLD-associated HCC development.
In summary, our study identified the AIM-dependent CDC
activation cascade that is effective for eliminating HCC cells.
This finding has the potential to open the door to developing
next-generation cancer therapies.
EXPERIMENTAL PROCEDURES
Mice
AIM/mice (Miyazaki et al., 1999) had been backcrossed to C57BL/6 (B6) for
13 generations before they were used for experiments. HFD (HFD32, fat kcal:
60%)was purchased fromCrea (Japan).C3/mice were purchased from The
Jackson Laboratory. All mice were maintained under specific-pathogen-free
conditions.
Antibodies, Cells, and Reagents
Antibodies and reagents used for histological and biochemical experiments
are as follows. Primary antibodies are F4/80 (RM2900, Caltag), AIM (rab2 rab-
bit polyclonal), FASN (Santa Cruz Biotechnology), MAC (Abcam), Ki67 (SP6,
Thermo Scientific), gp73 (Santa Cruz), Hep Par 1 (clone OCH1E5, Dako),
IgM (Molecular Probes), Complement C3 (11H9, Novus Biologicals), hemag-
glutinin (HA) tag (3F10, Roche), and Flag tag (M2, Sigma-Aldrich). Secondary
antibodies and related reagents are Alexa 488- or Alexa Fluor 594-, 633-, or
647-conjugated anti-rabbit, rat, goat immunoglobulin G (Molecular Probes),
DAPI (Roche), G-Block (Genostaff), and wheat germ agglutinin conjugated
with Alexa 594 (Life Technologies). Specimens were analyzed using a confocal
microscope: FV10i-DOC (Olympus). Murine and human HCC cell lines were
purchased from ATCC.
Purification of rAIM
CHO-S cell cells were transfected with pcDNA3.1-mAIM plasmid and cultured
in CD Forti CHOmedium (Invitrogen) for 3 days. rAIM was purified from culture
supernatant using rat anti-mouse AIM monoclonal antibody-conjugated Pro-
tein G Sepharose (GE Healthcare Life Sciences). Bound protein was eluted
with 0.1 M Glycin-HCl (pH 3.0) and neutralized with 1 M Tris-HCl (pH 8.5). Pro-
tein was concentrated as necessary using Amicon Ultra filter concentrators
(Millipore) and stored at 80C in PBS. Endotoxin levels were measured by
the chromogenic LAL endotoxin detection system (Genscript) following the
manufacturer’s protocols. Protein concentration was determined by a bicin-
choninic acid assay according to the manufacturer’s protocol (Pierce).
Mouse Primary Hepatocyte Isolation
Mouse primary hepatocytes were isolated by two-step collagenase perfusion
technique (Braun et al., 1988). Briefly, mice were anesthetized by 2.5% avertin
and liver were perfused via portal vein with perfusion buffer (Hank’s balanced
salt solution, 0.5 mM EGTA, 25 mM HEPES). Livers were then perfused with
digestion buffer (Dulbecco’s modified Eagle’s medium [DMEM], 100 CDU/ml
type 4 collagenase, 50 mg/ml trypsin inhibitor, 15mMHEPES). Liver were taken
into a Petri dish and dissociated by very gentle pipetting. Suspended cells
were filtered through a 150 mm nylon filter and centrifuged (50 3 g, 1 min,
4C). Cell pellets werewashed three timeswith DMEM/10% fetal bovine serum
(FBS). Cell viability was measured by trypan blue dye exclusion before they
were plated.
Liver Kupffer Cell Isolation
During the isolation of primary hepatocytes described above, the supernatant
fraction after the centrifuge of cell suspension of the dissociated liver tissue
contains Kupffer cells. The supernatant was further centrifuged (200 3 g,
5 min, 4C). Cell pellets were washed with DMEM/10% FBS and centrifuged
(50 3 g, 1 min, 4C). Resulting supernatant was centrifuged again (200 3 g,
5 min, 4C). This cycle was repeated four times to remove contaminated hepa-
tocyte. After the procedure, Kupffer cells were separated with F4/80 antibody72 Cell Reports 9, 61–74, October 9, 2014 ª2014 The Authorsusing MACS streptavidin microbeads. Cell viability was measured by trypan
blue dye exclusion before they were plated.
Fatty Acid Synthase Activity
The assay was performed as described previously (Kelley et al., 1986) with a
slight modification. Briefly, cell lysates from primary hepatocyte, or liver from
mice, were mixed with acetyl-coenzyme A and NADPH in 0.2 M potassium
phosphate buffer containing 0.4 mMEDTA (pH 7.0) and were added to a spec-
trophotometer cuvette thermostatted at 30C. The enzyme reaction was initi-
ated by adding 20 ml of malonyl-coenzyme A solution (0.2 mM), and the
decrease in optical density was chased at a chart speed of 2 cm/min. Based
on the results, the overall fatty acid synthase enzyme activity was estimated
by calculating the NADPH oxidized using ε = 6,220 M1cm1.
In Vitro Complement Activation Assay
Assessment of pathway activity in normal human serum samples using the
Complement System Alternative Pathway Kit (Wieslab). Ten different human
sera were loaded on the LPS-coated (2 mg/well) or human rAIM-coated
(2 mg/well) ELISA plates, and the plates were incubated to activate the comple-
ment cascade. MAC Formation was evaluated by the alkaline phosphatase-
conjugated anti-human MAC antibody provided by the kit. The institutional
committee for ethics approved our studies using human sera, and informed
consent was obtained from all subjects before the study started.
Statistical Analysis
A two-tailed Mann-Whitney test was used to calculate p values (***p < 0.001,
**p < 0.01, *p < 0.05). Error bars represent SEM.
Detailed descriptions about cell stress assay, liver triacylglycerol content,
metabolomics analysis, and quantitative PCR assay can be found in the Sup-
plemental Experimental Procedures.
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